Stocks Health care CYTK
NASDAQ · Health careCytokinetics Inc (CYTK)
Cytokinetics Inc brought in $113.3M of revenue over the twelve months to September 30, 2026, up 29.9% from a year earlier. It posted a net loss of $777.9M. In fiscal 2025 capital spending exceeded operating cash flow by $534.8M. At September 30, 2026 it held $203.4M in cash against $418.7M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Cytokinetics Inc
- Net worth
- Cytokinetics Inc has a market value (market cap) of $7.9B at the latest share price, and shareholders' equity of -$321.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $88M (+376.6% year on year), with a net loss of $785M. Over the 12 months to September 30, 2026: revenue $113.3M, net loss $777.9M.
- Cash flow
- In fiscal 2025 operations used $510M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Cytokinetics Inc's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Cytokinetics Inc does
Cytokinetics Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CYTK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $88M | -$785M | -$6.54 | -$534.8M |
| 2024 | $18.5M | -$589.5M | -$5.26 | -$399.8M |
| 2023 | $7.5M | -$526.2M | -$5.45 | -$415.7M |
| 2022 | $94.6M | -$389M | -$4.33 | -$310.9M |
| 2021 | $70.4M | -$215.3M | -$2.80 | -$191.4M |
| 2020 | $55.8M | -$127.3M | -$1.97 | -$2.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CYTK ranks in Health care
Latest SEC filings
What Cytokinetics Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 2,356% to $47.6M versus the same quarter last year; diluted EPS -$1.37 versus -$2.55.
- November 4, 2026
- August 28, 2026Other event 8-K
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Other event 8-K
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 57% to $28.6M versus the same quarter last year; diluted EPS -$1.50 versus -$1.12.
- August 6, 2026
- July 8, 2026Passive stake changed SCHEDULE 13G/A
- May 27, 2026
- May 27, 2026
Insider trades
What the people running Cytokinetics Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $11.9M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 3, 2026 | Malik Fady IbrahamEVP Research & Development | Exercised options | 3,500 | $27.3K |
| November 3, 2026 | Malik Fady IbrahamEVP Research & Development | Soldpre-planned (10b5-1) | 3,500 | $220.3K |
| November 2, 2026 | Blum Robert IPresident & CEO, Director | Exercised options | 7,500 | $79.5K |
| November 2, 2026 | Blum Robert IPresident & CEO, Director | Soldpre-planned (10b5-1) | 7,500 | $471.1K |
| October 20, 2026 | Malik Fady IbrahamEVP Research & Development | Exercised options | 3,500 | $27.3K |
| October 20, 2026 | Malik Fady IbrahamEVP Research & Development | Soldpre-planned (10b5-1) | 3,500 | $224K |
| October 16, 2026 | Henderson John TDirector | Received as pay | 352 | $22.5K |
| October 16, 2026 | Wierenga WendellDirector | Received as pay | 97 | $6.2K |
Who owns CYTK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 14.5% | February 17, 2026 |
| Vanguard Capital Management13G, passive | 5.21% | April 29, 2026 |
| Wellington Management Group LLP13G, passive with 2 related filers | 5.1% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 482 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 20,094,362 | +3,546,351 |
| Wellington Management Group Llp | 6,931,770 | -1,077,719 |
| Vanguard Portfolio Management LLC | 6,711,799 | +868,017 |
| State Street Corp | 6,494,233 | +749,040 |
| Vanguard Capital Management LLC | 6,117,515 | +628,881 |
| Fmr LLC | 5,031,782 | -5,691,358 |
| Avoro Capital Advisors LLC | 4,999,999 | +1,666,666 |
| Bank of America Corp | 4,635,709 | +1,510,273 |
| Geode Capital Management, LLC | 3,712,501 | +497,086 |
| Rtw Investments, LP | 2,862,003 | +140,845 |
| Polar Capital Holdings Plc | 2,253,649 | +592,401 |
| Goldman Sachs Group Inc | 1,761,588 | -444,170 |
| Capital Research Global Investors | 1,686,625 | +915,626 |
| Northern Trust Corp | 1,647,345 | +205,711 |
| Jpmorgan Chase & Co | 1,588,895 | +685,090 |
| William Blair Investment Management, LLC | 1,603,442 | +515,851 |
| Integral Health Asset Management, LLC | 1,600,000 | 0 |
| Point72 Asset Management, L.P. | 1,587,712 | +961,610 |
| Charles Schwab Investment Management Inc | 1,565,781 | +168,736 |
| Susquehanna International Group, Llp | 1,549,458 | +650,507 |
Insiders
14 insiders reported holding 892,296 shares in total, about $50.9M at the last price.
| Holder | Shares |
|---|---|
| Blum Robert IPresident & CEO, Director | 278,544 |
| Malik Fady IbrahamEVP Research & Development | 153,902 |
| Hessekiel JeffreyChief Legal & Admin Officer | 107,943 |
| Henderson John TDirector | 78,712 |
| Lee SungEVP, Chief Financial Officer | 63,221 |
| Callos AndrewEVP, Chief Commercial Officer | 58,555 |
| Wierenga WendellDirector | 35,660 |
| Wysenski NancyDirector | 34,089 |
| Bhanji MunaDirector | 26,361 |
| Harrington Robert ArthurDirector | 22,127 |
Questions about CYTK
What does Cytokinetics Inc do?
Cytokinetics Inc is a company in the Health care sector, listed on NASDAQ as CYTK. Its shares trade on NASDAQ under the ticker CYTK.
What is Cytokinetics Inc's net worth?
Cytokinetics Inc has a market value (market cap) of $7.9B at the latest share price, and shareholders' equity of -$321.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Cytokinetics Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $777.9M on revenue of $113.3M.
How much revenue does Cytokinetics Inc make?
Over the twelve months to September 30, 2026 Cytokinetics Inc reported revenue of $113.3M. That is 29.9% more than a year earlier.
When did Cytokinetics Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 9, 2026.
When is Cytokinetics Inc's next earnings report?
Cytokinetics Inc's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CYTK with
Follow CYTK
Get an email when Cytokinetics Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Cytokinetics Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.